EXACT Study - Emboshield and Xact Post Approval Carotid Stent Trial
Description of Research
The FDA has allowed the Emboshield filter and the Xact stent to be placed on the market and sold commercially in the United States. The purpose of this study is to collect more information on the safety and usefulness of the two devices now that they are commercially sold. This study will collect information about patients' medical history, the treatment itself, and any side effects.
Study Number
HSR 05-0582
Inclusion/Notes
All patients who have had Emboshield and/ or Xact inserted into theri vasculature
